Products
Latest News
FAQ
|
Search
Search
Filters
Clear All
Study Phase
Early Phase 1
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
Phase 4
Not Applicable
Recruitment Status
Recruiting
Not yet recruiting
Active, not recruiting
Completed
Suspended
Terminated
Withdrawn
Study Type
Interventional
Observational
Expanded Access
Others
Eligibility Sex
All
Female
Male
Healthy Volunteers
All
Include
Exclude
Found
1
clinical trials
|
View Analysis
Sort by:
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
Phase 2
Completed
Conditions
Acute Undifferentiated Leukemia
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified
Mixed Phenotype Acute Leukemia
Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified
Acute Bilineal Leukemia
Acute Biphenotypic Leukemia
Recurrent Mixed Phenotype Acute Leukemia
Interventions
Drug: Clofarabine
Drug: Cytarabine
Drug: Dexamethasone
Drug: Idarubicin
Biological: Rituximab
Drug: Sorafenib
Drug: Sorafenib Tosylate
Drug: Vincristine
Drug: Vincristine Sulfate
Subscribe
First Posted Date
2014-05-12
Last Posted Date
2024-03-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
16
Registration Number
NCT02135874
Locations
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Subscribe
Prev
1
Next
© Copyright 2025. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy